Marina Mencinger
About
Marina Mencinger is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Marina Mencinger has authored 21 papers receiving a total of 383 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 11 papers in Surgery and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Marina Mencinger's work include Cancer Immunotherapy and Biomarkers (13 papers), Bladder and Urothelial Cancer Treatments (11 papers) and Urinary and Genital Oncology Studies (6 papers). Marina Mencinger is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), Bladder and Urothelial Cancer Treatments (11 papers) and Urinary and Genital Oncology Studies (6 papers). Marina Mencinger collaborates with scholars based in Slovenia, Spain and Japan. Marina Mencinger's co-authors include Pierre Åman, Ioannis Panagopoulos, Felix Mitelman, Nils Mandahl, Carin Lassen, Håkan Toresson, Mattias Höglund, David Ron, Thoas Fioretos and Terence H. Rabbitts and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Oncogene.
In The Last Decade
Marina Mencinger
20 papers receiving 379 citations
Peers
Marina Mencinger
Iva Staniczková Zambo Czechia
Ali Fuat Okuducu Germany
Amanda T. McCleish United States
Sayaka Yuzawa Japan
Neera R. Nathan United States
Mark Veugelers Belgium
William W. Spurbeck United States
Silke Wemmert Germany
Vishwanathan Hucthagowder United States
Ana M. Figueiredo Portugal
Citations per year, relative to Marina Mencinger Marina Mencinger (= 1×)
peers
Iva Staniczková Zambo
Countries citing papers authored by Marina Mencinger
Since
Specialization
Citations
This map shows the geographic impact of Marina Mencinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marina Mencinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marina Mencinger more than expected).
Fields of papers citing papers by Marina Mencinger
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Marina Mencinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marina Mencinger. The network helps show where Marina Mencinger may publish in the future.
Co-authorship network of co-authors of Marina Mencinger
This figure shows the co-authorship network connecting the top 25 collaborators of Marina Mencinger. A scholar is included among the top collaborators of Marina Mencinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marina Mencinger. Marina Mencinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Mencinger, Marina, Veronika Kloboves Prevodnik, Srdjan Novaković, & Boštjan Šeruga. (2023). 2337P Feasibility of mutation detection in cytological samples from metastasis in patients with metastatic prostate cancer. Annals of Oncology. 34. S1192–S1192.
2.
Grande, Enrique, Aristotelis Bamias, Matt D. Galsky, et al.. (2023). Overall survival (OS) by response to first-line (1L) induction treatment with atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with metastatic urothelial carcinoma (mUC): Updated data from the IMvigor130 OS final analysis.. Journal of Clinical Oncology. 41(16_suppl). 4503–4503.
3.
Kuhar, Cvetka Grašič, Marina Mencinger, Tanja Ovčariček, et al.. (2023). Association of Circulating Tumor Cells, Megakaryocytes and a High Immune-Inflammatory Environment in Metastatic Breast Cancer. Cancers. 15(13). 3397–3397.
4.
Galsky, Matt D., Jóse Ángel Arranz Arija, Maria De Santis, et al.. (2023). Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem for first-line (1L) treatment (tx) of locally advanced or metastatic urothelial carcinoma (mUC): Final OS from the randomized Phase 3 IMvigor130 study.. Journal of Clinical Oncology. 41(6_suppl). LBA440–LBA440.
5.
Bamias, Aristotelis, Ian D. Davis, Matt D. Galsky, et al.. (2023). Final overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy (chemo) in untreated locally advanced or metastatic urothelial carcinoma (mUC) from the Phase 3 IMvigor130 study.. Journal of Clinical Oncology. 41(6_suppl). LBA441–LBA441.
6.
Thallinger, Christiane, Gabriella Fábián, Laurenţia Galeş, et al.. (2022). Establishment of a virtual transborder tumor board for cancer patients in Central and Southeastern Europe. Wiener klinische Wochenschrift. 134(19-20). 697–704.
7.
Mencinger, Marina, et al.. (2021). Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice. Radiology and Oncology. 55(4). 491–498.
8.
Grande, Enrique, Aristotelis Bamias, Matthew D. Galsky, et al.. (2021). Abstract CT187: Overall survival (OS) by response during “induction” from the global, randomized Phase III IMvigor130 study of atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with previously untreated metastatic urothelial carcinoma (mUC). Cancer Research. 81(13_Supplement). CT187–CT187.
9.
Galsky, Matthew D., José Ángel Arranz, Enrique Grande, et al.. (2021). Abstract CT042: Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Updated overall survival (OS) from the randomized phase III study IMvigor130. Cancer Research. 81(13_Supplement). CT042–CT042.
10.
Davis, Ian D., Matthew D. Galsky, Xavier García del Muro, et al.. (2021). Abstract CT040: Updated overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (mUC) in IMvigor130. Cancer Research. 81(13_Supplement). CT040–CT040.
11.
Bamias, Aristotelis, Maria De Santis, José Ángel Arranz, et al.. (2020). 698O Patient-reported outcomes (PROs) from IMvigor130: A global, randomised, partially blinded phase III study of atezolizumab (atezo) + platinum-based chemotherapy (PBC) vs placebo (PBO) + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC). Annals of Oncology. 31. S551–S552.
12.
Matos, Erika, et al.. (2020). Efficacy and safety of selective cyclin-dependent kinases 4/6 inhibitors in hormone-receptor-positive, HER2-negative advanced breast cancer – results from a real-world setting. Cancer Treatment and Research Communications. 25. 100201–100201.
13.
Kuhar, Cvetka Grašič, et al.. (2020). Efficacy of palbociclib after everolimus in hormone receptor-positive, HER2-negative advanced breast cancer.. Journal of Clinical Oncology. 38(15_suppl). e13030–e13030.
14.
Santis, Maria De, Enrique Grande, Marina Mencinger, et al.. (2020). IMvigor130 clinical trial in patients (pts) with metastatic urothelial carcinoma (mUC): Analysis of upper tract (UT) and lower tract (LT) subgroups.. Journal of Clinical Oncology. 38(6_suppl). 551–551.
15.
Grande, Enrique, Matt D. Galsky, Maria De Santis, et al.. (2019). IMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC). Annals of Oncology. 30. v888–v889.
16.
Mencinger, Marina & Pierre Åman. (1999). Characterization ofTFGinMus musculusandCaenorhabditis elegans. Biochemical and Biophysical Research Communications. 257(1). 67–73.
17.
Panagopoulos, Ioannis, Marina Mencinger, Claudia U. Dietrich, et al.. (1999). Fusion of the RBP56 and CHN genes in extraskeletal myxoid chondrosarcomas with translocation t(9;17)(q22;q11). Oncogene. 18(52). 7594–7598.
18.
Mencinger, Marina, Ioannis Panagopoulos, Juan Antonio Rojas‐Contreras, Felix Mitelman, & Pierre Åman. (1998). Expression analysis and chromosomal mapping of a novel human gene, APRIL, encoding an acidic protein rich in leucines. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression. 1395(2). 176–180.
19.
Mencinger, Marina, Ioannis Panagopoulos, Patrik Andreasson, et al.. (1997). Characterization and Chromosomal Mapping of the HumanTFGGene Involved in Thyroid Carcinoma. Genomics. 41(3). 327–331.
20.
Åman, Pierre, Ioannis Panagopoulos, Carin Lassen, et al.. (1996). Expression Patterns of the Human Sarcoma-Associated GenesFUSandEWSand the Genomic Structure ofFUS. Genomics. 37(1). 1–8.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Iva Staniczková Zambo Breakdown of academic impact, for papers by Ali Fuat Okuducu Breakdown of academic impact, for papers by Amanda T. McCleish Breakdown of academic impact, for papers by Sayaka Yuzawa Breakdown of academic impact, for papers by Neera R. Nathan Breakdown of academic impact, for papers by Mark Veugelers Breakdown of academic impact, for papers by William W. Spurbeck Breakdown of academic impact, for papers by Silke Wemmert Breakdown of academic impact, for papers by Vishwanathan Hucthagowder Breakdown of academic impact, for papers by Ana M. Figueiredo